RE:Waiting mode...
wildbird1 wrote: Nobody is really selling or buying big stack of shares. The shorts are down big time, the shorts seem to be betting on good results.
Look like everybody is waiting for results.
Keytruda is not a real competitor.
Keytruda TLT
-High toxicity - Low toxicity
-Low CR %(19%) -With the new optimized treatment..a much higher CR% is
expected.
-High number of treatments -1 or 2 treatments.
Unless somebody can find a real competitor, TLT for now is alone with a phase two treatment that target the worst of the worst bladder cancer patients.
Some people are talking about a buy out by big pharma.
TLT seem to be heading for a partnership. In TLT Corporate presentation (page 13), TLT said " Partner with big pharma to commercialize".
The advantage of a big pharma partner is TLT get a huge amount of money (many hundred of million $$$) as the deal is signed, and each year TLT get royalty on each patients treated.
Multiply the above for each new cancer treatment that TLT develop and get approved by the FDA.
Nice post wildbird1
Just to be clear, the CR rate for Keytruda was 41%. However, the CR at 12 months (durable response) was only 19%. As you succinctly alluded to, I still question if Keytruda even warranted an approval simply based on its risk:benefit ratio & the fact that this expensive treatment will only be used for a select group of patients in an already highly pre-treated population. Imo, there will be many physicians who will "not" be referring patients for Keytruda based on its marginal efficacy gains & the additional exorbitant costs...at least not specialists who are practicing responsible medicine from both an economic & life quality perspective. They are aware there is no standard of care (outside of bladder removal) for this disease & that state of the art treatment candidates are on the horizon. A BTD for TLT should be a big boost for patient enrollment imo.
In terms of a partnership, that does seem to be TLT's plan for the upcoming indication (GBM, NSCLC). They have not shown any intention/need for any type of agreement prior to NMIBC treatment approval. I am a big fan of a licensing partnership in the future for any additional indications to help expedite our drug development & expand commercial opportunities/financial gains (signing, milestone & royalty payments) while I'm still breathing ; ). Good luck...